

Approved for use through 10/31/2002, OMB 0651-0031
 Classification Number 09/873 881

(Use as many sheets as necessary)

2

Application Number	09/873,881
Filing Date	June 4, 2009
First Named Inventor	Scott, et al.
Group Art Unit	1648
Examiner Name	
Attorney Docket Number	18617.0075

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date 7/21/04
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

INFORMATIONAL STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	09/873,881
Filing Date	June 4, 2001
First Named Inventor	Scott, et al.
Group Art Unit	1648
Examiner Name	
Attorney Docket Number	18617.0075

Sheet 2 of 2



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initial	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	TECH CENTER 1600/2900
LO	1	HU et al., "Construction and Characterization of Raccoonpoxvirus (RCNV) Recombinant Expressing Feline Panleukopenia virus -vp2 (FPV), Rabies-G (RAB), and Feline Calicivirus (FCV) Capsid Proteins"; Abstract for ASV Meeting of July 9-13, 1994	
	2	LODMELL, et al., Raccoon Poxvirus Recombinants Expressing the Rabies Virus Nucleoprotein Protect Mice Against Lethal Rabies Virus Infection, Journal of Virology, June 1991, pp. 3400-3405.	
	3	PARRISH, et al., Canine Host Range and a Specific Epitope Map Along with Variant Sequences in the Capsid Protein Gene of Canine Parvovirus and Related Feline, Mink, and Raccoon Parvoviruses, Journal of Virology, 1988, 166:293-307	
	4	PARRISH, et al., Mapping Specific Functions in the Capsid Structure of Canine Parvovirus and Feline Panleukopenia Virus Using Infectious Plasmid Clones, Journal of Virology, 1991, 183:195-205.	
	5	MARTYN, et al., Nucleotide Sequence of Feline Panleukopenia Virus: Comparison With Canine Parvovirus Identifies Host-Specific Differences, Journal of General Virology, 1990, 71:2747-2753.	
	6	CARLSON, et al., Cloning and Sequence of DNA Encoding Structural Proteins of the Autonomous Parvovirus Feline Panleukopenia Virus, Journal of Virology, Sept. 1985, pp. 574-582.	
	7	ESPOSITO, et al., Successful Oral Rabies Vaccination of Raccoons With Raccoon Poxvirus Recombinants Expressing Rabies Virus Glycoprotein, Journal of Virology, 1988, 165:313-316.	
	8	VENNEMA, et al., Primary Structure of the Membrane and Nucleocapsid Protein Genes of Feline Infectious Peritonitis Virus and Immunogenicity of Recombinant Vaccinia Viruses in Kittens, Journal of Virology, 1991, 181:327-335.	
	9	FALKNER, et al., Escherichia Coli gpt Gene Provides Dominant Selection for Vaccinia Virus Open Reading Frame Expression Vectors, Journal of Virology, June 1988, Vol. 62, No. 6, pp. 1849-1854.	

Examiner Signature		Date	7/21/04
		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Assistant Commissioner for Patents, Washington, DC 20231.